Carisoprodol-Related Death in a Child

    Volume 20, Issue 1 (January 1975)

    ISSN: 0022-1198

    CODEN: JFSOAD

    Published Online: 1 January 1975

    Page Count: 3


    Morehead, CD
    RELA Schering Corp., Bloomfield, N.J.

    Adams, HR
    Toxicology and Pharmacology Laboratory, Department of Clinical Pathology, Scott and White Clinic, Temple, Texas

    Kerzee, T
    Chief, Scott and White Clinic, Temple, Texas

    (Received 15 April 1974; accepted 2 August 1974)

    Abstract

    Carisoprodol (N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate), a congener of meprobramate, is recommended by its manufacturers as a centrally acting musculoskeletal relaxant with mild anticholinergic, antipyretic, and analgesic properties. Many authorities maintain that the beneficial effects of carisoprodol noted in the treatment of patients with muscle spasm of local origin are related more to modification of central pain perception than they are to muscle relaxant properties [1,2]. Drowsiness, vertigo, weakness, and lassitude have accompanied carisoprodol therapy, but these adverse effects occur infrequently in adults who are taking recommended dosages of 250 or 350 mg four times daily [3].


    Paper ID: JFS10259J

    DOI: 10.1520/JFS10259J

    ASTM International
    is a member of CrossRef.

    Author
    Title Carisoprodol-Related Death in a Child
    Symposium , 0000-00-00
    Committee E30